Detalhe da pesquisa
1.
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay.
Br J Haematol
; 173(6): 884-95, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27071340
2.
Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial.
Clin Cancer Res
; 28(8): 1540-1548, 2022 04 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35140121
3.
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Blood
; 114(16): 3439-47, 2009 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-19671918
4.
Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.
Drug Metab Dispos
; 39(10): 1873-82, 2011 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-21752943
5.
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors.
Clin Cancer Res
; 27(18): 4994-5003, 2021 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34285061
6.
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Cancer Res
; 67(13): 6383-91, 2007 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17616698
7.
Development of proteasome inhibitors in oncology and autoimmune diseases.
Curr Opin Drug Discov Devel
; 11(5): 616-25, 2008 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-18729013
8.
Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
J Immunother Cancer
; 5(1): 101, 2017 12 19.
Artigo
Inglês
| MEDLINE | ID: mdl-29254508
9.
Drug discovery in the ubiquitin regulatory pathway.
Drug Discov Today
; 8(16): 746-54, 2003 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-12944097
10.
Fractal analysis in the detection of colonic cancer images.
IEEE Trans Inf Technol Biomed
; 6(1): 54-8, 2002 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-11936597
11.
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Mol Cancer Ther
; 13(4): 890-901, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24523301
12.
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
PLoS One
; 6(12): e27996, 2011.
Artigo
Inglês
| MEDLINE | ID: mdl-22216088
13.
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Clin Cancer Res
; 17(9): 2734-43, 2011 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-21364033
14.
Cellular localization and antiproliferative effect of peptides discovered from a functional screen of a retrovirally delivered random peptide library.
Chem Biol
; 10(10): 975-87, 2003 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-14583264
15.
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis.
Nat Med
; 15(7): 781-7, 2009 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-19525961
16.
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
J Med Chem
; 52(9): 3028-38, 2009 May 14.
Artigo
Inglês
| MEDLINE | ID: mdl-19348473
17.
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Blood
; 110(9): 3281-90, 2007 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-17591945
18.
Granular cell tumor as an unusual cause of obstruction at the hepatic hilum: report of a case.
Surg Today
; 36(10): 934-6, 2006.
Artigo
Inglês
| MEDLINE | ID: mdl-16998691
19.
A novel E3 ubiquitin ligase TRAC-1 positively regulates T cell activation.
J Immunol
; 174(9): 5288-97, 2005 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15843525
20.
Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.
Drug Resist Updat
; 5(6): 249-58, 2002 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-12531181